IBAT Inhibitor Therapy for PFIC Pruritus and Bile Acid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for progressive familial intrahepatic cholestasis (PFIC) and other inherited cholestatic liver diseases, such as Alagille syndrome (ALGS), are limited to surgical interventions like Partial External Biliary Diversion (PEBD) and liver transplantation, which carry significant risks and no medical therapy is available for ALGS, while existing medical treatments fail to effectively reduce pruritus and serum bile acid levels.
Innovation Solution
Oral administration of odevixibat, an ileal bile acid transport (IBAT) inhibitor, to reduce bile acid reabsorption, thereby decreasing serum bile acid levels and alleviating pruritus in patients with PFIC or ALGS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical interventions like PEBD or liver transplantation are used to treat PFIC, then liver function can be improved, but the treatment carries significant risks and complications
Solution Approach 1:
The patent replaces surgical mechanical interventions (PEBD, liver transplantation) with a pharmacological approach using IBAT inhibitors. The drug odevixibat orally administers to inhibit bile acid reabsorption in the ileum, achieving therapeutic effects without surgical risks. This substitutes the mechanical/surgical system with a chemical/pharmacological system that achieves the same goal of reducing bile acid levels and improving liver function.
2Ease of operation
If existing medical treatments are used for PFIC, then some symptoms can be managed, but they fail to effectively reduce pruritus and serum bile acid levels
Solution Approach 1:
The patent changes the pharmacological parameter by introducing a new mechanism of action - IBAT inhibition. Unlike existing treatments that may address symptoms generally, odevixibat specifically targets the bile acid reabsorption pathway by inhibiting the IBAT transporter in the ileum. This parameter change in the treatment mechanism enables significant reduction of serum bile acid levels and effective control of pruritus, overcoming the limitations of previous medical therapies.
3Adaptability or versatility
If no medical therapy is available for ALGS, then surgical options remain the only treatment, but this limits treatment accessibility and increases complexity
Solution Approach 1:
The patent demonstrates universality by showing that the IBAT inhibitor mechanism works across multiple disease types - both PFIC (progressive familial intrahepatic cholestasis) and ALGS (Alagille syndrome). The single drug odevixibat provides therapeutic benefit for different cholestatic liver diseases, eliminating the need for disease-specific treatments or surgical interventions for each condition. This multi-functional approach simplifies the treatment system and increases accessibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Odevixibat significantly reduces mean monthly pruritus score and serum bile acid concentration, normalizes growth parameters, and improves quality of life in patients with PFIC and ALGS, offering a non-surgical treatment option with fewer complications.
Implementation Method 1
Odevixibat is an inhibitor of the ileal bile acid transport (IBAT) mechanism. Specifically, odevixibat inhibits the natural reabsorption of bile acids from the ileum into the hepatic portal circulation.
Implementation Method 2
Bile acids that are not reabsorbed from the ileum are instead excreted into the feces.
Data Source
AI summary
Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.